FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2610510169> ?p ?o ?g. }

• W2610510169 abstract "Recent preclinical and phase I studies have reported that rebamipide decreased the severity of chemoradiotherapy-induced oral mucositis in patients with oral cancer. This placebo-controlled randomized phase II study assessed the clinical benefit of rebamipide in reducing the incidence of severe chemoradiotherapy-induced oral mucositis in patients with head and neck cancer (HNC). Patients aged 20–75 years with HNC who were scheduled to receive chemoradiotherapy were enrolled. Patients were randomized to receive rebamipide 2% liquid, rebamipide 4% liquid, or placebo. The primary endpoint was the incidence of grade ≥ 3 oral mucositis determined by clinical examination and assessed by central review according to the Common Terminology Criteria of Adverse Events version 3.0. Secondary endpoints were the time to onset of grade ≥ 3 oral mucositis and the incidence of functional impairment (grade ≥ 3) based on the evaluation by the Oral Mucositis Evaluation Committee. From April 2014 to August 2015, 97 patients with HNC were enrolled, of whom 94 received treatment. The incidence of grade ≥ 3 oral mucositis was 29% and 25% in the rebamipide 2% and 4% groups, respectively, compared with 39% in the placebo group. The proportion of patients who did not develop grade ≥ 3 oral mucositis by day 50 of treatment was 57.9% in the placebo group, whereas the proportion was 68.0% in the rebamipide 2% group and 71.3% in the rebamipide 4% group. The incidences of adverse events potentially related to the study drug were 16%, 26%, and 13% in the placebo, rebamipide 2%, and rebamipide 4% groups, respectively. There was no significant difference in treatment compliance among the groups. The present phase II study suggests that mouth washing with rebamipide may be effective and safe for patients with HNC receiving chemoradiotherapy, and 4% liquid is the optimal dose of rebamipide. ClinicalTrials.gov under the identifier NCT02085460 (the date of trial registration: March 11, 2014)." @default.
• W2610510169 created "2017-05-12" @default.
• W2610510169 creator A5000636193 @default.
• W2610510169 creator A5002918726 @default.
• W2610510169 creator A5003403184 @default.
• W2610510169 creator A5006414566 @default.
• W2610510169 creator A5011675274 @default.
• W2610510169 creator A5011876755 @default.
• W2610510169 creator A5018910129 @default.
• W2610510169 creator A5020649395 @default.
• W2610510169 creator A5029691234 @default.
• W2610510169 creator A5033390295 @default.
• W2610510169 creator A5043888846 @default.
• W2610510169 creator A5044638012 @default.
• W2610510169 creator A5046395258 @default.
• W2610510169 creator A5046622014 @default.
• W2610510169 creator A5049993042 @default.
• W2610510169 creator A5054908476 @default.
• W2610510169 creator A5060912740 @default.
• W2610510169 creator A5064820220 @default.
• W2610510169 creator A5066036934 @default.
• W2610510169 creator A5076120482 @default.
• W2610510169 creator A5079316471 @default.
• W2610510169 creator A5081561712 @default.
• W2610510169 creator A5087401551 @default.
• W2610510169 date "2017-05-05" @default.
• W2610510169 modified "2023-09-27" @default.
• W2610510169 title "Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study" @default.
• W2610510169 cites W108407377 @default.
• W2610510169 cites W1921819744 @default.
• W2610510169 cites W2004088421 @default.
• W2610510169 cites W201850683 @default.
• W2610510169 cites W2039983544 @default.
• W2610510169 cites W2046358333 @default.
• W2610510169 cites W2067222562 @default.
• W2610510169 cites W2075016350 @default.
• W2610510169 cites W2132864814 @default.
• W2610510169 cites W2141164707 @default.
• W2610510169 cites W2144367231 @default.
• W2610510169 cites W2158334747 @default.
• W2610510169 cites W2279336817 @default.
• W2610510169 cites W2328600084 @default.
• W2610510169 cites W2396121124 @default.
• W2610510169 cites W3190697283 @default.
• W2610510169 cites W1873062904 @default.
• W2610510169 doi "https://doi.org/10.1186/s12885-017-3295-4" @default.
• W2610510169 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5420134" @default.
• W2610510169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28476132" @default.
• W2610510169 hasPublicationYear "2017" @default.
• W2610510169 type Work @default.
• W2610510169 sameAs 2610510169 @default.
• W2610510169 citedByCount "21" @default.
• W2610510169 countsByYear W26105101692017 @default.
• W2610510169 countsByYear W26105101692018 @default.
• W2610510169 countsByYear W26105101692019 @default.
• W2610510169 countsByYear W26105101692020 @default.
• W2610510169 countsByYear W26105101692021 @default.
• W2610510169 countsByYear W26105101692022 @default.
• W2610510169 countsByYear W26105101692023 @default.
• W2610510169 crossrefType "journal-article" @default.
• W2610510169 hasAuthorship W2610510169A5000636193 @default.
• W2610510169 hasAuthorship W2610510169A5002918726 @default.
• W2610510169 hasAuthorship W2610510169A5003403184 @default.
• W2610510169 hasAuthorship W2610510169A5006414566 @default.
• W2610510169 hasAuthorship W2610510169A5011675274 @default.
• W2610510169 hasAuthorship W2610510169A5011876755 @default.
• W2610510169 hasAuthorship W2610510169A5018910129 @default.
• W2610510169 hasAuthorship W2610510169A5020649395 @default.
• W2610510169 hasAuthorship W2610510169A5029691234 @default.
• W2610510169 hasAuthorship W2610510169A5033390295 @default.
• W2610510169 hasAuthorship W2610510169A5043888846 @default.
• W2610510169 hasAuthorship W2610510169A5044638012 @default.
• W2610510169 hasAuthorship W2610510169A5046395258 @default.
• W2610510169 hasAuthorship W2610510169A5046622014 @default.
• W2610510169 hasAuthorship W2610510169A5049993042 @default.
• W2610510169 hasAuthorship W2610510169A5054908476 @default.
• W2610510169 hasAuthorship W2610510169A5060912740 @default.
• W2610510169 hasAuthorship W2610510169A5064820220 @default.
• W2610510169 hasAuthorship W2610510169A5066036934 @default.
• W2610510169 hasAuthorship W2610510169A5076120482 @default.
• W2610510169 hasAuthorship W2610510169A5079316471 @default.
• W2610510169 hasAuthorship W2610510169A5081561712 @default.
• W2610510169 hasAuthorship W2610510169A5087401551 @default.
• W2610510169 hasBestOaLocation W26105101691 @default.
• W2610510169 hasConcept C120665830 @default.
• W2610510169 hasConcept C121332964 @default.
• W2610510169 hasConcept C121608353 @default.
• W2610510169 hasConcept C126322002 @default.
• W2610510169 hasConcept C141071460 @default.
• W2610510169 hasConcept C142724271 @default.
• W2610510169 hasConcept C168563851 @default.
• W2610510169 hasConcept C197934379 @default.
• W2610510169 hasConcept C203092338 @default.
• W2610510169 hasConcept C204787440 @default.
• W2610510169 hasConcept C27081682 @default.
• W2610510169 hasConcept C2776530083 @default.
• W2610510169 hasConcept C2777367493 @default.
• W2610510169 hasConcept C2777793932 @default.
• W2610510169 hasConcept C2778424827 @default.
• W2610510169 hasConcept C2778496288 @default.

• next